All articles tagged with #trodelvy
A Phase 3 study shows that combining Gilead's Trodelvy with Merck's Keytruda significantly reduces tumor progression risk in women with aggressive triple-negative breast cancer, potentially leading to new treatment options.
Gilead announced that its antibody-drug conjugate Trodelvy failed to meet its primary endpoint in a Phase 3 study for bladder cancer, impacting the company's oncology business.
Gilead Sciences announced that the Phase 3 TROPiCS-04 study of Trodelvy in metastatic urothelial cancer did not meet its primary endpoint of overall survival. While some numerical improvements were observed, there were higher deaths due to adverse events with Trodelvy. Gilead will further investigate and discuss the results with the FDA. Trodelvy remains approved for other indications, and Gilead continues to explore its use in various cancers.
Gilead's stock dropped over 10% after disappointing results from a late-stage trial showed that its drug, Trodelvy, did not significantly extend the lives of patients with a certain type of lung cancer. Despite the drug already being approved for some types of breast and bladder cancers, the phase-three study aimed to expand its use. Gilead will discuss the results with regulators to determine if certain lung cancer patients may still benefit from the drug, which belongs to the sought-after class of antibody-drug conjugates. Analysts suggest that the trial results could impact investor confidence in Gilead's potential sales in oncology.
Gilead Sciences announced that its Phase 3 EVOKE-01 study evaluating Trodelvy did not meet its primary endpoint of overall survival in previously treated metastatic non-small cell lung cancer (NSCLC). Despite this, a numerical improvement in overall survival favoring Trodelvy was observed, particularly in patients non-responsive to last prior anti-PD-(L)1 therapy. Gilead plans to discuss the results with regulators and explore potential pathways to understand Trodelvy's role in these patients. The company remains confident in its broader lung cancer clinical development program and intends to present the data at an upcoming medical meeting. Trodelvy is the first approved Trop-2-directed antibody-drug conjugate for certain types of metastatic breast cancers and metastatic urothelial cancer, but its safety and efficacy for metastatic NSCLC have not been established.
Gilead Sciences' antibody drug conjugate, Trodelvy, did not significantly extend the lives of patients with metastatic non-small cell lung cancer in a recent study, raising questions about the effectiveness of this type of treatment in oncology. The disappointing results from the Evoke-01 study have implications for investors and oncologists, as antibody drug conjugates are considered a promising area in cancer treatment, combining an antibody with chemotherapy to target cancer cells.